Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

192 result(s)

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

    SARAH WATSON

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    BGB-LC-201
    A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI1438-0009 (DAREON 9)
    DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer

    PAULINE DU RUSQUEC

  • Lung cancer
    Paris
    BRIDGE (D9106C00002)
    A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

    NICOLAS GIRARD

  • Lung cancer
    Paris
    COCOON
    A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

    ELISA GOBBINI

  • Lung cancer
    Paris
    ENCO-BRAF (IFCT-1904)
    A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

    CLEMENCE BASSE

  • Breast cancer
    Saint-Cloud
    FAP-IT
    68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

  • Paris
    GCT1047-01
    First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    GSK213406
    A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

    FRANCOIS DOZ

  • ENT/Head and Neck Cancers
    Paris
    HPV.DCVax
    Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.

    CHRISTOPHE LE TOURNEAU

  • Paris, Saint-Cloud
    LE DECLIC-EPRI (IC 2019-06)
    DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.

    EVELYNE RENAULT TESSIER

  • Childhood and adolescent cancers
    Paris
    LYNPARZA (D0816C000025)
    A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours

    ISABELLE AERTS GAJDOS

  • Bladder cancer
    Paris
    MK3475-992
    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    MK7902-009 (LEAP-009)
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

    CHRISTOPHE LE TOURNEAU

  • Breast cancer
    Paris, Saint-Cloud
    MONDRIAN
    Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MS100070-0087
    Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.

    FRANCOIS DOZ

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    NIVOPOST-OP / GORTEC 2018-01
    A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

    CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC

  • Prostate cancer
    Paris
    PRESTO (GETUG-AFU 36)
    Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial

    GILLES CREHANGE

  • Lung cancer
    Paris, Saint-Cloud
    REAL MOOV LUNG
    Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ROMANCE (RAD05-UC-0107/1803)
    Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Paris, Saint-Cloud
    REVCCI
    Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

    ABDELMALEK GHIMOUZ

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Colorectal cancer
    Saint-Cloud
    ADAGE - Prodige 34
    Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.

  • Cancers gynécologiques
    Saint-Cloud
    AFTERGYN
    Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)

    DIANA BELLO ROUFAI

1 ...7
>